Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Incannex Healthcare (IXHL) Research & Development (2023 - 2025)

Incannex Healthcare's Research & Development history spans 3 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Research & Development rose 61.32% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $9.8 million, down 17.63%, while the annual FY2025 figure was $10.7 million, 16.55% down from the prior year.
  • Research & Development for Q4 2025 was $2.3 million at Incannex Healthcare, up from $1.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $4.4 million in Q2 2024 and bottomed at $1.1 million in Q3 2025.
  • The 3-year median for Research & Development is $2.7 million (2023), against an average of $2.7 million.
  • The largest YoY upside for Research & Development was 61.32% in 2025 against a maximum downside of 61.33% in 2025.
  • A 3-year view of Research & Development shows it stood at $2.6 million in 2023, then crashed by 46.4% to $1.4 million in 2024, then soared by 61.32% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for IXHL's Research & Development are $2.3 million (Q4 2025), $1.1 million (Q3 2025), and $3.7 million (Q2 2025).